Navigation Links
PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
Date:4/23/2008

ng and life-threatening disorder."

Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics added, "Initiation of the Phase 2b trial is an important milestone for PTC. The trial builds on the results we have achieved to date in DMD and cystic fibrosis (CF) and constitutes a major step forward in establishing the potential for PTC124 as a paradigm shift in the treatment of genetic disorders. Our future plans for PTC124 include the initiation of longer-term studies in CF, as well as additional proof-of-concept studies in other indications."

About Duchenne and Becker Muscular Dystrophy

Duchenne and Becker muscular dystrophy (DMD/BMD) are progressive muscle disorders that cause the loss of both muscle function and independence. DMD/BMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children). It is estimated that one in 10 DMD patients are likely to have a Becker presentation, a milder form of the disease that is associated with later manifestation of symptoms. In essence, DMD and BMD represent a continuum of the same disease. More information regarding DMD and BMD is available through the Muscular Dystrophy Association (http://www.mdausa.org), the Parent Project Muscular Dystrophy (http://www.parentprojectmd.org), and the Association Francaise contre les Myopathies (http://www.afm-france.org).

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely halt the translation process
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
2. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... Jersey's State-designated entity on behalf of the New Jersey Department of Health, has ... Health Information Technology, an agency of the U.S. Department of Health and Human ...
(Date:7/30/2015)... ... July 30, 2015 , ... 1Heart Caregiver Services LLC is offering its ... Make Money in the Booming Homecare Business.” This will be held in its main ... , The event will be hosted by 1Heart’s very own Randy Clarito (Director of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... Santa Rosa, CA (PRWEB) , ... July 30, 2015 , ... At the presentation of ... topic of discussion was focused on research presented by the Journal of Arthroplasty ... normal tasks – like driving. , Results of the study confirm what Santa ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... for women to ensure their children have the nutrition required to grow into ... by offering discount cards for many prescription pre-natal vitamins. , Folic Acid , ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4
... Innovative technology such as electronic wristbands is developed to ... Human errors. Wristbands are developed which provides information about ... used in hospitals now to prescribe, dispense and administer ... bands contain electronic system which is similar to the ...
... the clinical trials involving lung cancer patients and it ... a frontline therapy for those with lung cancer. One ... regime in the elderly patients is the tolerability and ... tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity ...
... of Fair Trading is responsible for checking the profits ... to the NHS. They have to monitor that only ... should be reasonable. ,The Pharmaceutical Price Regulation ... legislates the agreement of the pricing and quality of ...
... out of deprivation from being in poverty and poor ... for heart disease is potentially denying// life saving preventive ... published ahead of print in the journal Heart. ... being allocated "primary preventive" treatment, is currently calculated using ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
... called villi which increase the surface area of the intestine ... are covered in epithelial cells // which are constantly renewed ... top of the villi every day. ,Scientists found ... the bowel which, in healthy tissue, are immediately filled with ...
Cached Medicine News:Health News:Tarceva Found To Benefit Older Lung Cancer Patients 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Deprivation Can Cause Undetected Heart Problems 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2